MARKET

ATRA

ATRA

Atara Biotherape
NASDAQ
7.27
-0.15
-2.02%
After Hours: 7.63 +0.36 +4.95% 18:05 05/09 EDT
OPEN
7.44
PREV CLOSE
7.42
HIGH
7.80
LOW
7.27
VOLUME
26.42K
TURNOVER
--
52 WEEK HIGH
18.71
52 WEEK LOW
5.01
MARKET CAP
43.34M
P/E (TTM)
-0.6374
1D
5D
1M
3M
1Y
5Y
1D
FDA Lifts Hold on Atara’s EBVALLO Program
TipRanks · 3d ago
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Shares Fly 30% But Investors Aren't Buying For Growth
Simply Wall St · 4d ago
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 4d ago
Atara Biotherapeutics Says FDA Lifts Clinical Hold
Dow Jones · 4d ago
Atara Biotherapeutics Provides Regulatory Updates On EBVALLO; FDA Lifts Clinical Hold Enabling Resumption Of Clinical Trials; FDA Has Granted A Type A Meeting To Discuss Path Forward For BLA
Benzinga · 4d ago
Atara Biotherapeutics: FDA lifts clinical hold on IND applications for Ebvallo
TipRanks · 4d ago
ATARA BIOTHERAPEUTICS INC - FDA HAS GRANTED A TYPE A MEETING TO DISCUSS PATH FORWARD FOR BLA
Reuters · 4d ago
Atara Biotherapeutics Provides Regulatory Updates on EBVALLO™ (tabelecleucel)
Barchart · 4d ago
More
About ATRA
More
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company. The Company is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. Its pipeline products include Ebvallo (Tab-cel), ATA3219. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA3219 is in Phase 1 development is being developed as a potential product intended to target B-cell malignancies and autoimmune diseases, based on a next generation 1XX co-stimulatory domain and the innate advantages of EBV T cells as the foundation for an allogeneic CAR T platform.
Recently
Symbol
Price
%Change

Webull offers Atara Biotherapeutics Inc stock information, including NASDAQ: ATRA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATRA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ATRA stock methods without spending real money on the virtual paper trading platform.